Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120

NCT02208882 ↗

Phase 1 Completed 24 enrolled Bristol-Myers Squibb

RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to assess the safety, tolerability and effect on Midazolam pharmacokinetics of multiple oral doses of BMS-986120 in healthy subjects.

Timeline

Start: 2014-08
Primary completion: 2015-02
Completion: 2015-02

Publications

Merali S, Wang Z, Frost C, Callejo M, Hedrick M, Hui L, Meadows Shropshire S, Xu K, Bouvier M, DeSouza MM, Yang J. New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans. Platelets. 2022 Oct 3;33(7):969-978. doi: 10.1080/09537104.2022.2088719. Epub 2022 Jun 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986120	Unknown	—	Oral
Subject	Midazolam	Small molecule	—	Oral

Indications

No indication recorded.